Related Experiment Video
Updated: Jan 15, 2026
07:24
Reduction in Left Ventricular Wall Stress and Improvement in Function in Failing Hearts using Algisyl-LVR
Published on: April 8, 2013
24.7K
Early SGLT2i Therapy Facilitates In-Hospital ARNI Introduction Improving 6-Month Systolic Function in Patients with
Andrea D'Amato1, Silvia Prosperi1, Federico Ferranti1
1Department of Clinical, Internal, Anesthesiology and Cardiovascular Sciences, Sapienza University of Rome, 00161, Rome, Italy.
Summary
Starting sodium-glucose co-transporter 2 inhibitors (SGLT2i) in the hospital for heart failure with reduced ejection fraction (HFrEF) increases the likelihood of introducing angiotensin receptor-neprilysin inhibitors (ARNI). This early SGLT2i strategy also improves left ventricular systolic function.
Area of Science:
- Cardiology
- Pharmacology
- Clinical Medicine
Background:
- Heart failure with reduced ejection fraction (HFrEF) requires timely disease-modifying therapies.
- Optimal timing for initiating HFrEF therapies in-hospital is under investigation.
Purpose of the Study:
- To evaluate if early in-hospital sodium-glucose co-transporter 2 inhibitors (SGLT2i) initiation facilitates angiotensin receptor-neprilysin inhibitors (ARNI) introduction.
- To assess if this strategy improves left ventricular systolic function at 6 months.
Main Methods:
- Prospective, observational, single-centre study of consecutive HFrEF patients.
- Two groups: Group 1 (in-hospital SGLT2i initiation) and Group 2 (post-discharge SGLT2i initiation).
- Comparison of ARNI introduction during hospitalization and echocardiographic parameters at 6-month follow-up.
Main Results:
- Early in-hospital SGLT2i predicted ARNI initiation before discharge (OR: 3.31, p<0.001).
- In G1, combined SGLT2i and ARNI therapy predicted LVEF improvement (>10%) at 6 months (OR: 5.353, p<0.003).
Conclusions:
- Early in-hospital SGLT2i initiation in HFrEF patients increases the likelihood of in-hospital ARNI introduction.
- This strategy is associated with significant improvements in left ventricular systolic function at 6-month follow-up.
Related Concept Videos
01:30Heart Failure V: Medical Management
218
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
218
01:22Heart Failure VI: Adjunct Therapies
255
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
255
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
932
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
932
01:25Aortic Regurgitation III: Medical Management
396
Aortic regurgitation (AR) is when the aortic valve does not close or seal properly, leading to backward blood circulation from the aorta into the left ventricle during diastole. Common causes of AR include rheumatic heart disease, congenital valve defects, and aortic root dilation. Managing AR requires a multifaceted approach to alleviate symptoms, preserve left ventricular function, and address the underlying cause of the regurgitation. Patients with symptomatic AR or significant left...
396
01:29Cardiomyopathy V: Interprofessional Care
338
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
338
01:21Rheumatic Heart Disease III: Medical Management
285
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
285